

Steve Sisolak
Governor



Richard Whitley, MS
Director

DEPARTMENT OF HEALTH AND HUMAN SERVICES

DIVISION OF HEALTH CARE FINANCING AND POLICY

Helping people. It's who we are and what we do.



Suzanne Bierman,
JD MPH
Administrator

NOTICE OF MEETING TO SOLICIT PUBLIC COMMENTS AND INTENT TO ACT UPON AMENDMENTS TO THE NEVADA MEDICAID SERVICES MANUAL (MSM)

REVISED AGENDA

Date of Publication:	December 30, 2022
Date of Revision:	January 19, 2023
Date and Time of Meeting:	January 31, 2023 at 10:05 AM or upon completion of the amendments to the State Plan for Medicaid Services Public Hearing immediately preceding this meeting at the same location(s)
Name of Organization:	The State of Nevada, Department of Health and Human Services (DHHS), Division of Health Care Financing and Policy (DHCFP)
Place of Meeting:	DHCFP 1100 East William Street First Floor Conference Room Carson City, Nevada 89701

Please use the teleconference/Microsoft Teams options provided below. If accommodations are requested, please advise using the information at the end of this agenda.

Note: If at any time during the meeting an individual who has been named on the agenda or has an item specifically regarding them included on the agenda is unable to participate because of technical or other difficulties, please email Jenifer Graham at documentcontrol@dhcfp.nv.gov and note at what time the difficulty started so that matters pertaining specifically to their participation may be continued to a future agenda if needed or otherwise addressed.

Please be cautious and do not click on links in the chat area of the meeting unless you have verified they are safe. If you ever have questions about a link in a document purporting to be from Nevada Medicaid, please do not hesitate to contact documentcontrol@dhcfp.nv.gov for verification.

Webinar: <https://tinyurl.com/DHCFP2023PH>

Select "Join," enter your name and email and then select "Join."

The meeting should not require a password.

Audio Only: (775) 321-6111
Conference ID: 934 453 822#

**PLEASE DO NOT PUT THIS NUMBER ON HOLD (*hang up and rejoin if you must take another call*)
YOU MAY BE UNMUTED BY THE HOST WHEN SEEKING PUBLIC COMMENT, PLEASE HANG UP AND REJOIN IF YOU ARE
HAVING SIDE CONVERSATIONS DURING THE MEETING OR THOSE MAY BE HEARD BY OTHERS AND RECORDED**

**This meeting may be recorded to facilitate note-taking or other uses. By participating you consent to recording of
your participation in this meeting.**

AGENDA

1. General Public Comments (Because of time considerations, the period for public comment by each speaker or organization may be limited to three minutes and speakers are urged to avoid repetition of comments made by previous speakers.)
2. **For possible action:** Discussion and adoption of changes to MSM Chapter 1200 – Prescribed Drugs

Revisions to MSM Chapter 1200 – Prescribed Drugs to reflect recommendations approved on October 20, 2022, by the Drug Utilization Review (DUR) Board. The proposed changes include the addition of new prior authorization criteria for Vivjoa® (oteseconazole) within the Anti-Fungal Agents section; addition of new prior authorization criteria for Voquenza® Dual Pak® (Vonoprazan and amoxicillin), and Voquenza® Triple Pak® (Vonoprazan, amoxicillin, and clarithromycin) within the new Qualified Infection Disease Product Section; addition of new prior authorization criteria for Livtency® (maribravir) in the Antivirals section; addition of new prior authorization criteria for Cuvrior® (trientine tetrahydrochloride) within the new Copper Chelator section; addition of new prior authorization criteria for Pyrukynd® (mitapivat) within the new Pyruvate Kinase Activators section; revisions to the existing Provigil® (modafinil) and Nuvigil® (armodafinil) for the treatment of Obstructive Sleep Apnea (OSA) within the Narcolepsy Agents section; addition of new prior authorization criteria for Kynmobi® (apomorphine) in the new Anti-Parkinson’s Agents section; addition of new prior authorization criteria for Amvuttra® (Vutrisiran) within the new Amyloidosis-Agents Transthyretin (TTR) Suppression (P9B) section; revisions to the existing immunomodulator drugs criteria; revision to the existing Topical Androgens and Gender Edits, which include the addition of new prior authorization for Oral testosterone products within the Hormones and Hormones Modifiers section; addition of new prior authorization for Oxervate®(cenegermin-bkbj) within the new Ophthalmic Human Nerve Growth Factor (Q25) Section.

Entities Financially Affected: Providers who prescribe, dispense or administer this drug may be affected by this change, including but not limited to the following Provider Types (PTs): Outpatient Surgery (PT 10); Hospital, Inpatient (PT 11); Hospital, Outpatient (PT 12); Intermediate Care Facilities for Individuals with Intellectual Disabilities, Public (PT 16); Special Clinics (PT 17); Nursing Facility (PT 19); Physician/Osteopath (PT 20); Podiatrist (PT21); Advanced Practice Registered Nurse (PT 24); Pharmacy (PT 28); Home Health Agency (PT 29); Ambulatory Surgical Centers, Freestanding (PT 46); Indian Health Programs and Tribal Clinics (PT 47); Indian Health Service Hospital, Inpatient (Tribal) (PT 51), Indian Health Service Hospital, Outpatient (Tribal) (PT52); Transitional Rehabilitative Center, Outpatient (PT 55); Inpatient Rehabilitation and Long Term Acute Care (LTAC) Specialty Hospitals (PT 56); Hospice (PT 64); Hospice, Long Term Care (PT 65); Intermediate Care Facilities for Individuals with Intellectual Disabilities, Private (PT68); Nurse Anesthetist (PT 72); Critical Access Hospital (CAH), Inpatient (PT 75); Audiologist (PT 76); Physician’s Assistant (PT 77); Indian Health Service Hospital, Inpatient (Non-Tribal) (PT 78); Indian Health Service Hospital, Outpatient (Non-Tribal) (PT 79).

Financial impact on local government: No known financial impact of local government.

Effective date: ~~January 31, 2023~~ February 6, 2023.

- a. Presentation of MSM Chapter 1200

